Pediatric Cardiology

, Volume 32, Issue 8, pp 1106–1109 | Cite as

Prediction of the Risk of Coronary Arterial Lesions in Kawasaki Disease by Brain Natriuretic Peptide

  • Kazunari Kaneko
  • Ken Yoshimura
  • Atsushi Ohashi
  • Takahisa Kimata
  • Tomohiko Shimo
  • Shoji Tsuji
Original Article

Abstract

Kawasaki disease (KD) is an acute systemic vasculitis associated with the development of coronary arterial lesions (CALs) occurring in 3–5% of children treated by intravenous immune globulin (IVIG). However, a considerable number of patients who are not responding to IVIG are at much higher risk. Although studies have explored potential biomarkers to predict patients with KD who are at risk of CAL, no useful single marker exists. We hypothesized that the serum concentrations of the N-terminal moiety of brain natriuretic peptide (NT-proBNP) can be useful to predict CAL. Forty-three children with KD (29 males and 14 females) were enrolled in this study. Despite IVIG, 6 of the 43 patients developed CAL. There were, however, no significant differences in variables between children with CAL and those without CAL: These include age, gender, day of the illness, leukocyte count, and the serum levels of sodium, C-reactive protein, and albumin. The serum NT-proBNP level was significantly higher in children with CAL than those without CAL (2,611 ± 1,699 vs. 1,073 ± 1,427 pg/ml; P = 0.03): the cutoff value of 1,000 pg/ml to predict CAL produced a specificity of 0.68, sensitivity of 0.83, and an odds ratio as high as 10.4. In conclusion, NT-proBNP is increased in KD patients who are developing CAL, and patients with an elevated serum NT-proBNP >1,000 pg/ml have a risk of CAL ~10 times higher than that of patients with a modest increase.

Keywords

Kawasaki disease Coronary arterial lesion Brain natriuretic peptide 

References

  1. 1.
    Albers S, Mir TS, Haddad M, Läer S (2006) N-terminal pro brain natriuretic peptide: evaluation of pediatric reference values including method comparison and interlaboratory variability. Clin Chem Lab Med 44:80–85PubMedCrossRefGoogle Scholar
  2. 2.
    Beiser AS, Takahashi M, Baker AL, Sundel RP, Newburger JW (1998) A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol 81:1116–1120PubMedCrossRefGoogle Scholar
  3. 3.
    Burns JC (2007) The riddle of Kawasaki disease. N Engl J Med 356:659–661PubMedCrossRefGoogle Scholar
  4. 4.
    Burns JC, Glodé MP (2004) Kawasaki syndrome. Lancet 364:533–544PubMedCrossRefGoogle Scholar
  5. 5.
    Dahdah N, Siles A, Fournier A, Cousineau J, Delvin E, Saint-Cyr C, Spiegelblatt L, Bonny Y, Vartian M, Montigny M (2009) Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol 30:810–817PubMedCrossRefGoogle Scholar
  6. 6.
    Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C (2003) Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 24:145–148PubMedCrossRefGoogle Scholar
  7. 7.
    Japan Kawasaki Disease Research Committee (1984) Diagnostic guidelines of Kawasaki disease. 4th rev. ed. Japan Kawasaki Disease Committee, TokyoGoogle Scholar
  8. 8.
    Kawamura T, Wago M (2002) Brain natriuretic peptide can be a useful biochemical marker for myocarditis in patients with Kawasaki disease. Cardiol Young 12:153–158PubMedCrossRefGoogle Scholar
  9. 9.
    Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M (2000) Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 42:241–248PubMedCrossRefGoogle Scholar
  10. 10.
    Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A (2006) Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113:2606–2612PubMedCrossRefGoogle Scholar
  11. 11.
    Kobayashi T, Inoue Y, Otani T, Morikawa A, Kobayashi T, Takeuchi K, Saji T, Sonobe T, Ogawa S, Miura M, Arakawa H (2009) Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease. Pediatr Infect Dis J 28:498–502PubMedCrossRefGoogle Scholar
  12. 12.
    Kurotobi S, Kawakami N, Shimizu K, Aoki H, Nasuno S, Takahashi K, Kogaki S, Ozono K (2005) Brain natriuretic peptide as a hormonal marker of ventricular diastolic dysfunction in children with Kawasaki disease. Pediatr Cardiol 26:425–430PubMedCrossRefGoogle Scholar
  13. 13.
    Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, Mukoyama M, Nakao K (1993) Increased serum levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88:82–91PubMedGoogle Scholar
  14. 14.
    Mukoyama M, Nakao K, Saito Y, Ogawa Y, Hosoda K, Suga S, Shirakami G, Jougasaki M, Imura H (1990) Human brain natriuretic peptide, a novel cardiac hormone. Lancet 335:801–802PubMedCrossRefGoogle Scholar
  15. 15.
    Muta H, Ishii M, Furui J, Nakamura Y, Matsuishi T (2006) Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease. Acta Paediatr 95:189–193PubMedCrossRefGoogle Scholar
  16. 16.
    Nakamura Y, Yashiro M, Uehara R, Watanabe M, Tajimi M, Oki I, Ojima T, Sonobe T, Yanagawa H (2004) Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 46:33–38PubMedCrossRefGoogle Scholar
  17. 17.
    Song D, Yeo Y, Ha K, Jang G, Lee J, Lee K, Son C, Lee J (2009) Risk factors for Kawasaki disease-associated coronary abnormalities differ depending on age. Eur J Pediatr 168:1315–1321PubMedCrossRefGoogle Scholar
  18. 18.
    Tang WH (2007) B-type natriuretic peptide: a critical review. Congest Heart Fail 13:48–52PubMedCrossRefGoogle Scholar
  19. 19.
    Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90:195–203PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Kazunari Kaneko
    • 1
  • Ken Yoshimura
    • 1
  • Atsushi Ohashi
    • 1
  • Takahisa Kimata
    • 1
  • Tomohiko Shimo
    • 1
  • Shoji Tsuji
    • 1
  1. 1.Department of PediatricsKansai Medical UniversityOsakaJapan

Personalised recommendations